These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36557319)

  • 21. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms.
    Spigset O; Granberg K; Hägg S; Norström A; Dahlqvist R
    Eur J Clin Pharmacol; 1997; 52(2):129-33. PubMed ID: 9174682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancy.
    Abduljalil K; Pansari A; Jamei M
    J Pharmacokinet Pharmacodyn; 2020 Aug; 47(4):361-383. PubMed ID: 32840724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of CYP2D6 Phenotypes on the Pharmacokinetics of Aripiprazole and Dehydro-Aripiprazole Using a Physiologically Based Pharmacokinetic Approach.
    Kneller LA; Zubiaur P; Koller D; Abad-Santos F; Hempel G
    Clin Pharmacokinet; 2021 Dec; 60(12):1569-1582. PubMed ID: 34125422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan.
    Barbhaiya RH; Buch AB; Greene DS
    Br J Clin Pharmacol; 1996 Nov; 42(5):573-81. PubMed ID: 8951188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steady-state pharmacokinetics of the enantiomers of perhexiline in CYP2D6 poor and extensive metabolizers administered Rac-perhexiline.
    Davies BJ; Herbert MK; Coller JK; Somogyi AA; Milne RW; Sallustio BC
    Br J Clin Pharmacol; 2008 Mar; 65(3):347-54. PubMed ID: 17875193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adjusting the dose of tamoxifen in patients with early breast cancer and CYP2D6 poor metabolizer phenotype.
    Martinez de Dueñas E; Ochoa Aranda E; Blancas Lopez-Barajas I; Ferrer Magdalena T; Bandrés Moya F; Chicharro García LM; Gómez Capilla JA; Zafra Ceres M; de Haro T; Romero Llorens R; Ferrer Albiach C; Ferriols Lisart R; Chover Lara D; López Rodríguez A; Munárriz Ferrandis J; Olmos Antón S
    Breast; 2014 Aug; 23(4):400-6. PubMed ID: 24685597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy.
    Bastian JR; Chen H; Zhang H; Rothenberger S; Tarter R; English D; Venkataramanan R; Caritis SN
    Am J Obstet Gynecol; 2017 Jan; 216(1):64.e1-64.e7. PubMed ID: 27687214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphisms in the 5-hydroxytryptamine 2A receptor and CytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in japanese depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Neuropsychopharmacology; 2006 Apr; 31(4):825-31. PubMed ID: 16205777
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Absolute oral bioavailability of traxoprodil in cytochrome P450 2D6 extensive and poor metabolisers.
    Taylor TJ; Diringer K; Russell T; Venkatakrishnan K; Wilner K; Crownover PH; Benincosa LJ; Gibbs MA
    Clin Pharmacokinet; 2006; 45(10):989-1001. PubMed ID: 16984212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline.
    Alfaro CL; Lam YW; Simpson J; Ereshefsky L
    J Clin Psychopharmacol; 1999 Apr; 19(2):155-63. PubMed ID: 10211917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The major fluvoxamine metabolite in urine is formed by CYP2D6.
    Spigset O; Axelsson S; Norström A; Hägg S; Dahlqvist R
    Eur J Clin Pharmacol; 2001 Nov; 57(9):653-8. PubMed ID: 11791895
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacokinetics of atomoxetine.
    Sauer JM; Ring BJ; Witcher JW
    Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The natural interleukin-1 receptor antagonist in the fetal, maternal, and amniotic fluid compartments: the effect of gestational age, fetal gender, and intrauterine infection.
    Romero R; Gomez R; Galasso M; Mazor M; Berry SM; Quintero RA; Cotton DB
    Am J Obstet Gynecol; 1994 Oct; 171(4):912-21. PubMed ID: 7943101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients.
    Katoh Y; Uchida S; Kawai M; Takei N; Mori N; Kawakami J; Kagawa Y; Yamada S; Namiki N; Hashimoto H
    Biol Pharm Bull; 2010; 33(2):285-8. PubMed ID: 20118554
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.
    Schalkwijk S; Buaben AO; Freriksen JJM; Colbers AP; Burger DM; Greupink R; Russel FGM
    Clin Pharmacokinet; 2018 Jun; 57(6):705-716. PubMed ID: 28744795
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of antenatal steroid therapy is dependent on the duration of low-concentration fetal exposure: evidence from a sheep model of pregnancy.
    Kemp MW; Saito M; Usuda H; Watanabe S; Sato S; Hanita T; Kumagai Y; Molloy TJ; Clarke M; Eddershaw PJ; Musk GC; Schmidt A; Ireland D; Furfaro L; Payne MS; Newnham JP; Jobe AH
    Am J Obstet Gynecol; 2018 Sep; 219(3):301.e1-301.e16. PubMed ID: 29758177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.
    Costantine MM; West H; Wisner KL; Caritis S; Clark S; Venkataramanan R; Stika CS; Rytting E; Wang X; Ahmed MS;
    Am J Obstet Gynecol; 2021 Dec; 225(6):666.e1-666.e15. PubMed ID: 34033812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dose-dependent effect of the CYP2D6 genotype on the steady-state fluvoxamine concentration.
    Watanabe J; Suzuki Y; Fukui N; Sugai T; Ono S; Inoue Y; Someya T
    Ther Drug Monit; 2008 Dec; 30(6):705-8. PubMed ID: 18978520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.